12:00 AM
Jan 04, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Celebrex celecoxib COX-2 specific inhibitor regulatory update

The FDA granted marketing approval for Celebrex as an oral adjunct to usual care to treat familial adenomatous...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >